Le Lézard
Classified in: Health
Subject: FDA

Getinge recieves FDA premarket approval for the iCasttm covered stent system in the US


GOTHENBURG, Sweden, March 24, 2023 /PRNewswire/ -- Getinge's iCasttm covered stent system has received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with iliac arterial occlusive disease.

Iliac arterial occlusive disease is a type of peripheral arterial disease (PAD), a serious condition that only in the US affects 8 million persons,1 in which atherosclerosis narrows and blocks peripheral arteries. As the world population ages and rates of diabetes and obesity rise, it is estimated that more people will be affected with iliac artery disease.

"We are pleased that the iCasttm stent system is approved in the United States for use in iliac arteries to benefit an even greater number of patients", says Elin Frostehav, President Acute Care Therapies at Getinge. "The global market for covered stents is growing at an annual rate of 5%. Getinge will continue to ramp up capacity throughout the year in order to meet the demand."

The iCast covered stent system, which is sold outside the US under the brand name Advanta V12 covered stent, has been used by clinicians for 20 years and is the most clinically evaluated balloon expandable polytetrafluoroethylene (ePTFE)-covered stent in the world, with clinical data published in more than 550 articles.

Media contact:

Anna Appelqvist, Corporate Communications
Phone: +46 (0)10 335 5906
Email: [email protected]

About Getinge

Getinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people, today and tomorrow.

1 Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5?S67

The following files are available for download:

https://mb.cision.com/Main/942/3740488/1940861.pdf

Getinge recieves FDA premarket approval for the iCastâ?¢ covered stent system in the US

https://news.cision.com/getinge/i/elin-1200x600,c3159934

Elin 1200x600

https://news.cision.com/getinge/i/icast-stent,c3159948

iCast stent

 

SOURCE Getinge


These press releases may also interest you

at 20:23
Fluence, a global leader in evidence-based psychedelic therapy training, has announced a partnership with Metamorph AI, a pioneering AI technology company, to develop an AI-powered tool to enhance the training of psychedelic therapists. We believe...

at 18:30
Next Gen Diagnostics (NGD) and a team at Vanderbilt University Medical Center (VUMC) today announced the results of a study reporting that comparison of the whole genome sequence (WGS) of bacterial pathogens obtained from surveillance of infants in a...

at 17:21
Community Healthcare Trust Incorporated (the "Company") today announced the release of its inaugural Corporate Sustainability Report for the year 2023. This comprehensive report highlights the Company's commitment to environmental stewardship,...

at 17:14
BJC HealthCare, one of the largest nonprofit health care organizations in the United States, and Encompass Health , the nation's largest owner and operator of inpatient rehabilitation hospitals, announce the opening of The Rehabilitation Institute of...

at 17:04
Cano Health, Inc. ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced a global agreement with the Unsecured Creditors Committee representing the interests of the Company's...

at 17:00
Eupraxia Pharmaceuticals...



News published on and distributed by: